We are live on ! Find out more
DRUG

Bright Minds Biosciences

64 hedge funds and large institutions have $366M invested in Bright Minds Biosciences in 2025 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 22 increasing their positions, 13 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,700% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 1

167% more capital invested

Capital invested by funds: $137M → $366M (+$229M)

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

69% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 13

36% more funds holding

Funds holding: 4764 (+17)

11.42% more ownership

Funds ownership: 74.34%85.76% (+11%)

Holders
64
Holders Change
+17
Holders Change %
+36.17%
% of All Funds
0.84%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
18
Increased
22
Reduced
13
Closed
1
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Janus Henderson Group
1
Janus Henderson Group
United Kingdom
$69.1M
CAM
2
Cormorant Asset Management
Massachusetts
$64.3M
VC
3
Vivo Capital
California
$30.4M +$9.71M +250,045 +99%
CC
4
Commodore Capital
New York
$30.3M
PA
5
Perceptive Advisors
New York
$27.3M +$1.11M +28,600 +7%
Adage Capital Partners
6
Adage Capital Partners
Massachusetts
$24M +$7.6M +195,743 +98%
B
7
Braidwell
Connecticut
$18.4M +$11.8M +303,685 New
BlackRock
8
BlackRock
New York
$14.2M +$949K +24,441 +12%
Morgan Stanley
9
Morgan Stanley
New York
$11.7M +$1.2M +30,797 +19%
SCM
10
Sio Capital Management
New York
$11.6M -$12.5M -321,574 -63%
Balyasny Asset Management
11
Balyasny Asset Management
Illinois
$11.3M +$7.26M +186,922 New
Point72 Asset Management
12
Point72 Asset Management
Connecticut
$6.37M -$1.16M -30,000 -22%
ACP
13
Acuta Capital Partners
California
$5.15M +$1.41M +36,401 +75%
Millennium Management
14
Millennium Management
New York
$4.65M -$1.35M -34,690 -31%
Walleye Capital
15
Walleye Capital
New York
$4.41M +$750K +19,324 +36%
State Street
16
State Street
Massachusetts
$4.15M +$1.7M +43,733 +177%
SSA
17
Schonfeld Strategic Advisors
New York
$4.04M -$93.1K -2,398 -3%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$3.51M +$14.7K +378 +0.7%
SCM
19
Superstring Capital Management
New York
$3.27M +$2.09M +53,950 New
Vanguard Group
20
Vanguard Group
Pennsylvania
$2.74M +$509K +13,120 +41%
PIM
21
Platinum Investment Management
Australia
$1.72M
BFM
22
Boothbay Fund Management
New York
$1.71M +$348K +8,955 +47%
Northern Trust
23
Northern Trust
Illinois
$1.65M +$61.6K +1,587 +6%
Jane Street
24
Jane Street
New York
$965K +$617K +15,903 New
IC
25
Ikarian Capital
Texas
$936K -$1.94M -50,000 -76%

DRUG Hedge Fund Activity: Q3 2025 in Review

64 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Bright Minds Biosciences (DRUG) for Q3 2025, worth a combined $366M — up 167% from $137M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new DRUG positions and 1 closed out — a net gain of 17 holders — while 22 added to existing stakes and 13 trimmed.

The largest buyer was Braidwell, opening a new position worth an estimated $11.8M. The largest seller was Sio Capital Management, cutting an estimated $12.5M.

  • 64 institutional investors held Bright Minds Biosciences (DRUG) as of Q3 2025, up from 47 in Q2 2025.
  • Funds reported $366M of Bright Minds Biosciences stock for Q3 2025, up 167% quarter-over-quarter.
  • 18 funds opened new Bright Minds Biosciences positions in Q3 2025 and 1 closed out, a net change of +17 holders.
  • The largest Bright Minds Biosciences buyer in Q3 2025 was Braidwell, an estimated $11.8M added.
  • The largest Bright Minds Biosciences seller in Q3 2025 was Sio Capital Management, an estimated $12.5M sold.

Based on aggregated 13F filings for Q3 2025.